US Pharma MarketingADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the ch For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the chronic weight management market it had ceded to rival Eli Lilly in the U.S. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report…
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral GLP-1 for obesity—marked an opportunity to recapture some of the chronic weight management market it had ceded to rival Eli Lilly in the U.S.
Source: FiercePharma